The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
Open accessAbstract
The Parkinson's disease (PD) substantia nigra is characterized by the presence of Lewy bodies containing fibrillar α-synuclein. Early-onset PD has been linked to two point mutations in the gene that encodes α-synuclein, suggesting that disease may arise from accelerated fibrillization. However, the identity of the pathogenic species and its relationship to the α-synuclein fibril has not been elucidated. In this in vitro study, the rates of disappearance of monomeric α-synuclein and appearance of fibrillar α-synuclein were compared for the wild-type (WT) and two mutant proteins, as well as equimolar mixtures that may model the heterozygous PD patients. Whereas one of the mutant proteins (A53T) and an equimolar mixture of A53T and WT fibrillized more rapidly than WT α-synuclein, the other (A30P) and the corresponding equimolar mixture with WT fibrillized more slowly. However, under conditions that ultimately produced fibrils, the A30P monomer was consumed at a comparable rate or slightly more rapidly than the WT monomer, whereas A53T was consumed even more rapidly. The difference between these trends suggested the existence of nonfibrillar α-synuclein oligomers, some of which were separated from fibrillar and monomeric α-synuclein by sedimentation followed by gel-filtration chromatography. Spheres (range of heights: 2–6 nm), chains of spheres (protofibrils), and rings resembling circularized protofibrils (height: ca. 4 nm) were distinguished from fibrils (height: ca. 8 nm) by atomic force microscopy. Importantly, drug candidates that inhibit α-synuclein fibrillization but do not block its oligomerization could mimic the A30P mutation and thus may accelerate disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Self-citationHarper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652
Self-citation(1998) · Europe PMC (PubMed Central) · Cited by 1,594
NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded
Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., & Lansbury, P. T. (1996) · Biochemistry · doi:10.1021/bi961799n · Cited by 1,523
Self-citationConway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Self-citation
Cited by
Items 101–191 of 191
Prefibrillar Amyloid Protein Aggregates Share Common Features of Cytotoxicity
Bucciantini, M., Calloni, G., Chiti, F., Formigli, L., Nosi, D., Dobson, C. M., & Stefani, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400348200 · Cited by 369
Pathological roles of α-synuclein in neurological disorders
Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., & Stefanis, L. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70213-7 · Cited by 357
Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line
Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., & Brundin, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205518200 · Cited by 352
Functions and dysfunctions of nitric oxide in brain
Picón-Pagès, P., Garcia-Buendia, J., & Muñoz, F. J. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.007 · Cited by 347
Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders
Ingelsson, M. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00408 · Cited by 344
The role of α-synuclein in Parkinson's disease: insights from animal models
Maries, E., Dass, B., Collier, T. J., Kordower, J. H., & Steece-Collier, K. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1199 · Cited by 344
Cohlberg, J. A., Li, J., Uversky, V. N., & Fink, A. L. (2002) · Biochemistry · doi:10.1021/bi011711s · Cited by 340
Implications of peptide assemblies in amyloid diseases
Ke, P. C., Sani, M.-A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T. P., & Mezzenga, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00372b · Cited by 338
Flagmeier, P., Meisl, G., Vendruscolo, M., Knowles, T. P. J., Dobson, C. M., Buell, A. K., & Galvagnion, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604645113 · Cited by 333
Sharon, R., Goldberg, M. S., Bar-Josef, I., Betensky, R. A., Shen, J., & Selkoe, D. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171300598 · Cited by 328
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease
Büeler, H. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.006 · Cited by 327
Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Uversky, V., & Eliezer, D. (2009) · Current Protein & Peptide Science · doi:10.2174/138920309789351921 · Cited by 322
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
α‐Synuclein and Parkinson's disease
Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D., & Giusti, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0338rev · Cited by 318
Alexander, A. G., Marfil, V., & Li, C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00279 · Cited by 310
Protein Misfolding, Amyloid Formation, and Neurodegeneration
Muchowski, P. J. (2002) · Neuron · doi:10.1016/s0896-6273(02)00761-4 · Cited by 308
Curcumin Modulates α-Synuclein Aggregation and Toxicity
Singh, P. K., Kotia, V., Ghosh, D., Mohite, G. M., Kumar, A., & Maji, S. K. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn3001203 · Cited by 307
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities
Alam, P., Bousset, L., Melki, R., & Otzen, D. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14808 · Cited by 307
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E., & Masliah, E. (2004) · Experimental Neurology · doi:10.1016/s0014-4886(03)00342-x · Cited by 295
Gosavi, N., Lee, H.-J., Lee, J. S., Patel, S., & Lee, S.-J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208194200 · Cited by 294
Self-citationBartels, T., Ahlstrom, L. S., Leftin, A., Kamp, F., Haass, C., Brown, M. F., & Beyer, K. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.06.035 · Cited by 292
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M. G., & Feany, M. B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0285-07.2007 · Cited by 292
Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity
Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P., & Krainc, D. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5575-11.2012 · Cited by 291
Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors
Lee, H.-J., Shin, S. Y., Choi, C., Lee, Y. H., & Lee, S.-J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105326200 · Cited by 291
Self-citationAccelerated α‐synuclein fibrillation in crowded milieu
Uversky, V. N., M. Cooper, E., Bower, K. S., Li, J., & Fink, A. L. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02446-8 · Cited by 291
Life on the edge: a link between gene expression levels and aggregation rates of human proteins
Tartaglia, G. G., Pechmann, S., Dobson, C. M., & Vendruscolo, M. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.03.005 · Cited by 289
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
Mutation E46K increases phospholipid binding and assembly into filaments of human α‐synuclein
Choi, W., Zibaee, S., Jakes, R., Serpell, L. C., Davletov, B., Anthony Crowther, R., & Goedert, M. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.038 · Cited by 286
Functional Consequences of α-Synuclein Tyrosine Nitration
Hodara, R., Norris, E. H., Giasson, B. I., Mishizen-Eberz, A. J., Lynch, D. R., Lee, V. M.-Y., & Ischiropoulos, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408906200 · Cited by 286
Miller, Y., Ma, B., & Nussinov, R. (2010) · Chemical Reviews · doi:10.1021/cr900377t · Cited by 286
Alpha-synuclein: from secretion to dysfunction and death
Marques, O., & Outeiro, T. F. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.94 · Cited by 286
α-Synuclein and dopamine at the crossroads of Parkinson's disease
Venda, L. L., Cragg, S. J., Buchman, V. L., & Wade-Martins, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.004 · Cited by 285
Secondary Structure of α-Synuclein Oligomers: Characterization by Raman and Atomic Force Microscopy
Apetri, M. M., Maiti, N. C., Zagorski, M. G., Carey, P. R., & Anderson, V. E. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.10.071 · Cited by 283
Tsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003135 · Cited by 281
RetractedGiasson, B. I., Ischiropoulos, H., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00804-3 · Cited by 279
Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S., & Selkoe, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.545749 · Cited by 279
Alpha-synuclein and Parkinson's disease
Lücking, C. B., & Brice*, A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000671 · Cited by 279
Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins
Perrin, R. J., Woods, W. S., Clayton, D. F., & George, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105022200 · Cited by 279
Van der Perren, A., Gelders, G., Fenyi, A., Bousset, L., Brito, F., Peelaerts, W., Van den Haute, C., Gentleman, S., Melki, R., & Baekelandt, V. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02157-3 · Cited by 277
Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273
Chiti, F., Calamai, M., Taddei, N., Stefani, M., Ramponi, G., & Dobson, C. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212527999 · Cited by 273
Proteome analysis of human substantia nigra in Parkinson's disease
Basso, M., Giraudo, S., Corpillo, D., Bergamasco, B., Lopiano, L., & Fasano, M. (2004) · PROTEOMICS · doi:10.1002/pmic.200400848 · Cited by 271
Cao, S., Gelwix, C. C., Caldwell, K. A., & Caldwell, G. A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5157-04.2005 · Cited by 271
Yamada, M., Iwatsubo, T., Mizuno, Y., & Mochizuki, H. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02728.x · Cited by 270
Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model
Hamamichi, S., Rivas, R. N., Knight, A. L., Cao, S., Caldwell, K. A., & Caldwell, G. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711018105 · Cited by 268
Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice
Rey, N. L., Petit, G. H., Bousset, L., Melki, R., & Brundin, P. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1160-3 · Cited by 267
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
Dev, K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 263
Biochemical Characterization of the Core Structure of α-Synuclein Filaments
Miake, H., Mizusawa, H., Iwatsubo, T., & Hasegawa, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110551200 · Cited by 260
Cappai, R., Leck, S., Tew, D. J., Williamson, N. A., Smith, D. P., Galatis, D., Sharpies, R. A., Curtain, C. C., Ali, F. E., Cherny, R. A., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3437fje · Cited by 257
Quantification of α-Synuclein Binding to Lipid Vesicles Using Fluorescence Correlation Spectroscopy
Rhoades, E., Ramlall, T. F., Webb, W. W., & Eliezer, D. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.079251 · Cited by 257
Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein
Bussell, R., & Eliezer, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106777200 · Cited by 255
Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., Hoener, M., Rodrigues, C. M. P., Alfonso, A., Steer, C., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505910200 · Cited by 255
The Role of Stable α-Synuclein Oligomers in the Molecular Events Underlying Amyloid Formation
Lorenzen, N., Nielsen, S. B., Buell, A. K., Kaspersen, J. D., Arosio, P., Vad, B. S., Paslawski, W., Christiansen, G., Valnickova-Hansen, Z., Andreasen, M., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411577t · Cited by 255
Genetic clues to the pathogenesis of Parkinson's disease
Vila, M., & Przedborski, S. (2004) · Nature Medicine · doi:10.1038/nm1068 · Cited by 255
Interpreting the Aggregation Kinetics of Amyloid Peptides
Pellarin, R., & Caflisch, A. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.05.033 · Cited by 254
Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
Choi, M. L., Chappard, A., Singh, B. P., Maclachlan, C., Rodrigues, M., Fedotova, E. I., Berezhnov, A. V., De, S., Peddie, C. J., Athauda, D., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01140-3 · Cited by 254
Lázaro, D. F., Rodrigues, E. F., Langohr, R., Shahpasandzadeh, H., Ribeiro, T., Guerreiro, P., Gerhardt, E., Kröhnert, K., Klucken, J., Pereira, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004741 · Cited by 252
Molecular pathogenesis of Parkinson's disease
Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi308 · Cited by 251
Uchihara, T., & Giasson, B. I. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1485-1 · Cited by 249
“While some reports suggest that A30P αS forms amyloid fibrils more slowly than wild-type (WT) αS [37], this finding has not been consistently observed by others [67, 138].”
ResultRole of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus
Ashraf, G., Greig, N., Khan, T., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I., Zaidi, S., Akram, M., Jabir, N., et al. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917095514 · Cited by 236
Membrane Protein Structure, Function, and Dynamics: a Perspective from Experiments and Theory
Cournia, Z., Allen, T. W., Andricioaei, I., Antonny, B., Baum, D., Brannigan, G., Buchete, N.-V., Deckman, J. T., Delemotte, L., del Val, C., et al. (2015) · The Journal of Membrane Biology · doi:10.1007/s00232-015-9802-0 · Cited by 235
Neurotoxic protein oligomers — what you see is not always what you get
Bitan, G., Fradinger, E. A., Spring, S. M., & Teplow, D. B. (2005) · Amyloid · doi:10.1080/13506120500106958 · Cited by 221
Trimethylamine‐ N ‐oxide‐induced folding of α‐synuclein
Uversky, V. N., Li, J., & Fink, A. L. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03121-0 · Cited by 208
Tau Oligomers Impair Artificial Membrane Integrity and Cellular Viability
Flach, K., Hilbrich, I., Schiffmann, A., Gärtner, U., Krüger, M., Leonhardt, M., Waschipky, H., Wick, L., Arendt, T., & Holzer, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396176 · Cited by 188
The Insulin/Akt Signaling Pathway Is Targeted by Intracellular β-Amyloid
Lee, H.-K., Kumar, P., Fu, Q., Rosen, K. M., & Querfurth, H. W. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-07-0777 · Cited by 185
Yanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171
α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration
Mosharov, E. V., Staal, R. G. W., Bové, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M. H., Troyer, M. D., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0519-06.2006 · Cited by 165
Assessment of α-Synuclein Secretion in Mouse and Human Brain Parenchyma
Emmanouilidou, E., Elenis, D., Papasilekas, T., Stranjalis, G., Gerozissis, K., Ioannou, P. C., & Vekrellis, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022225 · Cited by 163
“. The mechanism of involvement of α-synuclein in PD is not well understood, although there is evidence that abnormal folding plays a critical role in the pathogenesis of the disease and that the toxic α-synuclein species may be oligomeric intermediates”
BackgroundYu, W. H., Dorado, B., Figueroa, H. Y., Wang, L., Planel, E., Cookson, M. R., Clark, L. N., & Duff, K. E. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080928 · Cited by 155
Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148
Tóth, G., Gardai, S. J., Zago, W., Bertoncini, C. W., Cremades, N., Roy, S. L., Tambe, M. A., Rochet, J.-C., Galvagnion, C., Skibinski, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087133 · Cited by 151
Self-citationBurke, K. A., Yates, E. A., & Legleiter, J. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00017 · Cited by 127
Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121
Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine
Castino, R., Lazzeri, G., Lenzi, P., Bellio, N., Follo, C., Ferrucci, M., Fornai, F., & Isidoro, C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05488.x · Cited by 115
Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease
Mullin, S., & Schapira, A. H. V. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.010 · Cited by 108
Parkinsons Disease and other α-Synucleinopathies
Goedert, M. (2001) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2001.047 · Cited by 96
Olivares, D., Huang, X., Branden, L., Greig, N. H., & Rogers, J. T. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10031226 · Cited by 93
Low‐n oligomers as therapeutic targets of Alzheimer’s disease
Ono, K., & Yamada, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07187.x · Cited by 76
Su, C., Yang, X., & Lou, J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.011 · Cited by 75
Cebrián, C., Loike, J. D., & Sulzer, D. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_356 · Cited by 65
Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Kang, L., Wu, K.-P., Vendruscolo, M., & Baum, J. (2011) · Journal of the American Chemical Society · doi:10.1021/ja203979j · Cited by 65
Liu, D., Guo, J.-J., Su, J.-H., Svanbergsson, A., Yuan, L., Haikal, C., Li, W., Gouras, G., & Li, J.-Y. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00242-5 · Cited by 32
Heterogeneity in α-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia
Sokratian, A., Ziaee, J., Kelly, K., Chang, A., Bryant, N., Wang, S., Xu, E., Li, J. Y., Wang, S.-H., Ervin, J., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02288-1 · Cited by 34
Rivero-Ríos, P., Romo-Lozano, M., Fasiczka, R., Naaldijk, Y., & Hilfiker, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00556 · Cited by 31
Ahmed, R., Huang, J., Weber, D. K., Gopinath, T., Veglia, G., Akimoto, M., Khondker, A., Rheinstädter, M. C., Huynh, V., Wylie, R. G., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c01894 · Cited by 28
The N Terminus of α‐Synuclein Forms Cu II ‐Bridged Oligomers
Drew, S. C. (2015) · Chemistry – A European Journal · doi:10.1002/chem.201500236 · Cited by 26
Intramolecular interaction kinetically regulates fibril formation by human and mouse α-synuclein
Ohgita, T., Kono, H., Morita, I., Oyama, H., Shimanouchi, T., Kobayashi, N., & Saito, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-38070-4 · Cited by 20
Metadata
- Authors
- Conway, K. A., Lee, S.-J., Rochet, J.-C., Ding, T. T., Williamson, R. E., & Lansbury, P. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-01-18
- Volume
- 97
- Issue
- 2
- Pages
- 571-576
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2009556855
- Cited by
- 1,541
- References
- 44
- FWCI
- 36.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.